Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (321-330 of 361) with videos related to

Pageof 37
Sort By:
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Leukemia|January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human studyNoffar Bar, Thomas Martin, Craig C Hofmeister, et al.
Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.
Cancer Medicine|October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple MyelomaNiels W C J van de Donk, Ajai Chari, Thomas Martin, et al.
Cytogenetic and Genome Research|April 10, 2014
Mitotic stability of small supernumerary marker chromosomes: a study based on 93 immortalized cell linesHannes Spittel, Florian Kubek, Katharina Kreskowski, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
International Journal of Molecular Medicine|May 29, 2008
Thirty-two new cases with small supernumerary marker chromosomes detected in connection with fertility problems: detailed molecular cytogenetic characterization and review of the literatureMarina Manvelyan, Mariluce Riegel, Monica Santos, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Pageof 37

Showing results (321-330 of 361) with videos related to

Sort By:
Pageof 37
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Leukemia|January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human studyNoffar Bar, Thomas Martin, Craig C Hofmeister, et al.
Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.
Cancer Medicine|October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple MyelomaNiels W C J van de Donk, Ajai Chari, Thomas Martin, et al.
Cytogenetic and Genome Research|April 10, 2014
Mitotic stability of small supernumerary marker chromosomes: a study based on 93 immortalized cell linesHannes Spittel, Florian Kubek, Katharina Kreskowski, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
International Journal of Molecular Medicine|May 29, 2008
Thirty-two new cases with small supernumerary marker chromosomes detected in connection with fertility problems: detailed molecular cytogenetic characterization and review of the literatureMarina Manvelyan, Mariluce Riegel, Monica Santos, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Pageof 37